MX2008009592A - Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. - Google Patents

Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.

Info

Publication number
MX2008009592A
MX2008009592A MX2008009592A MX2008009592A MX2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A MX 2008009592 A MX2008009592 A MX 2008009592A
Authority
MX
Mexico
Prior art keywords
ovarian cancer
methods
increased likelihood
biomarkers
screening methods
Prior art date
Application number
MX2008009592A
Other languages
English (en)
Inventor
Timothy J Fischer
Clark M Whitehead
Douglas P Malinowski
Qin He
Robert L Cheek
John W Groelke
Original Assignee
Tripath Imaging Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tripath Imaging Inc filed Critical Tripath Imaging Inc
Publication of MX2008009592A publication Critical patent/MX2008009592A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Abstract

Se proporcionan métodos de análisis para Identificar pacientes con una probabilidad incrementada de tener cáncer de ovario. Los métodos de análisis involucran te detección de la expresión de una pluralidad de biomarcadores en una muestra corporal, en donde la sobre- expresión de los biomarcadores es indicativa de una probabilidad incrementada de tener cáncer de ovario. Los métodos de análisis además pueden comprender un análisis de dos etapas. Los biomarcadores de interés incluyen genes y proteínas que están, por ejemplo, involucradas en la replicación de ADN/control del ciclo celular, crecimiento celular y proliferación, escape de apoptósis, angiogénesis o linfogénesis o los mecanismos de la motilidad e invasión celular cancerosa. En algunos aspectos de la invención, la expresión de un biomarcador está detectada en el nivel de proteína usando un anticuerpo biomarcador-específico o en el nivel del ácido nucleico usando las técnicas de hibridación de ácido nucleico. Los métodos para detectar el cáncer de ovario en los pacientes además se describe en este documento. También se proporcionan los equipos para practicar los métodos de la invención.
MX2008009592A 2006-01-27 2007-01-29 Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario. MX2008009592A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76276006P 2006-01-27 2006-01-27
PCT/US2007/061205 WO2007090076A2 (en) 2006-01-27 2007-01-29 Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor

Publications (1)

Publication Number Publication Date
MX2008009592A true MX2008009592A (es) 2008-09-08

Family

ID=38328113

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008009592A MX2008009592A (es) 2006-01-27 2007-01-29 Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.

Country Status (11)

Country Link
US (3) US20070212721A1 (es)
EP (2) EP1987360B1 (es)
JP (1) JP2009524438A (es)
KR (1) KR20080094803A (es)
CN (1) CN101410715A (es)
AT (1) ATE548656T1 (es)
AU (1) AU2007211085A1 (es)
BR (1) BRPI0707249A2 (es)
CA (1) CA2637446A1 (es)
MX (1) MX2008009592A (es)
WO (1) WO2007090076A2 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213720A1 (en) * 2000-11-01 2002-05-15 Mount Sinai Hospital Detection of ovarian cancer
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
AU2006335290A1 (en) 2006-01-11 2007-07-19 Raindance Technologies, Inc. Microfluidic devices and methods of use in the formation and control of nanoreactors
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
US20080014589A1 (en) 2006-05-11 2008-01-17 Link Darren R Microfluidic devices and methods of use thereof
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
CA2652562C (en) 2006-05-17 2015-05-12 Cellumen, Inc. Method for automated tissue analysis
CN101449162B (zh) 2006-05-18 2013-07-31 分子压型学会股份有限公司 确定针对病状的个性化医疗介入的系统和方法
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US20100009352A1 (en) * 2006-05-24 2010-01-14 Gough Albert H Method for Modeling a Disease
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
EP2095119A2 (en) * 2006-11-10 2009-09-02 Cellumen, Inc. Protein-protein interaction biosensors and methods of use thereof
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
MX2009009450A (es) * 2007-03-09 2009-12-01 Tripath Imaging Inc Anticuerpos monoclonales para he4 y metodos para su uso.
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US20090087849A1 (en) * 2007-09-06 2009-04-02 Tripath Imaging, Inc. Nucleic acid-based methods and compositions for the detection of ovarian cancer
US20090130195A1 (en) * 2007-10-17 2009-05-21 Mildred Acevedo-Duncan Prostate carcinogenesis predictor
EP2088204A1 (en) * 2008-02-05 2009-08-12 Adnagen AG Method and kit for diagnosing or controlling the treatment of ovarian cancer
EP4047367A1 (en) 2008-07-18 2022-08-24 Bio-Rad Laboratories, Inc. Method for detecting target analytes with droplet libraries
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA2737004A1 (en) * 2008-10-06 2010-04-15 Somalogic, Inc. Ovarian cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
KR20110110247A (ko) * 2008-12-30 2011-10-06 센토코 오르토 바이오테크 인코포레이티드 강직성 척추염 환자에서 항-ＴＮＦα 항체에 대한 임상적 반응을 예측하는 혈청 마커
US20100227335A1 (en) * 2009-03-05 2010-09-09 Becton, Dickinson And Company Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
US8252904B2 (en) * 2009-03-06 2012-08-28 Tripath Imaging, Inc. Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
EP2411148B1 (en) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation of microfluidic droplets
EP2486409A1 (en) 2009-10-09 2012-08-15 Universite De Strasbourg Labelled silica-based nanomaterial with enhanced properties and uses thereof
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
WO2011100453A2 (en) * 2010-02-10 2011-08-18 Maine Medical Center Compositions and methods for the treatment of cardiac and vascular disease
EP2534267B1 (en) 2010-02-12 2018-04-11 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
CN104777313B (zh) 2010-07-09 2017-09-26 私募蛋白质体公司 肺癌生物标记及其用途
WO2012021795A2 (en) 2010-08-13 2012-02-16 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
US9562897B2 (en) 2010-09-30 2017-02-07 Raindance Technologies, Inc. Sandwich assays in droplets
WO2012092336A2 (en) * 2010-12-28 2012-07-05 Caris Mpi, Inc. Molecular profiling for cancer
EP3412778A1 (en) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Methods for forming mixed droplets
RU2650778C2 (ru) * 2011-02-17 2018-04-17 Фуджиребио Диагностикс, Инк Композиции и способы применения для определения не4а
EP2675819B1 (en) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
DE112012000990T5 (de) * 2011-02-24 2014-03-27 Vermillion, Inc. Biomarker-Panels, Diagnostische Verfahren und Testkits für Eierstockkrebs
CA2830501C (en) 2011-03-17 2023-10-17 Cernostics, Inc. Systems and compositions for diagnosing barrett's esophagus and methods of using the same
CN102735840B (zh) * 2011-04-13 2014-06-04 中国医学科学院肿瘤研究所 用于诊断或筛查卵巢癌的试剂
WO2012142330A1 (en) * 2011-04-15 2012-10-18 Brown University Micro rnas as diagnostic biomarkers and therapeutics for ovarian cancer and metastatic tumors that disseminate within the peritoneal cavity
DE202012013668U1 (de) 2011-06-02 2019-04-18 Raindance Technologies, Inc. Enzymquantifizierung
WO2012167278A1 (en) * 2011-06-02 2012-12-06 Almac Diagnostics Limited Molecular diagnostic test for cancer
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2721417A4 (en) * 2011-06-17 2015-05-06 Univ Arkansas NEW MARKERS FOR EARLY DIAGNOSIS OF EGG CANCER, MONITORING DURING THE CORRESPONDING THERAPY AND NEW THERAPY OPTIONS DURING AND AFTER THE CORRESPONDING CHEMOTHERAPY
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
EP2925885B1 (en) 2012-12-03 2020-02-05 Almac Diagnostic Services Limited Molecular diagnostic test for cancer
CN105264374A (zh) * 2013-03-27 2016-01-20 赛拉诺斯股份有限公司 用于样品分析的方法、装置和系统
WO2014172288A2 (en) 2013-04-19 2014-10-23 Raindance Technologies, Inc. Digital analyte analysis
WO2015039175A1 (en) * 2013-09-18 2015-03-26 Adelaide Research & Innovation Pty Ltd Autoantibody biomarkers of ovarian cancer
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US11221327B2 (en) * 2013-10-10 2022-01-11 Mcmaster University Method for diagnosing and monitoring inflammatory disease progression
CN103525941A (zh) * 2013-10-29 2014-01-22 上海市奉贤区中心医院 Cthrc1基因在制备检测/治疗宫颈癌药物中的应用
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
EP3090063B1 (en) 2013-12-31 2019-11-06 Bio-Rad Laboratories, Inc. Method for detection of latent retrovirus
GB201409479D0 (en) 2014-05-28 2014-07-09 Almac Diagnostics Ltd Molecular diagnostic test for cancer
CN111718413A (zh) * 2015-06-26 2020-09-29 上海市肿瘤研究所 Cthrc1在肝硬化诊断和治疗中的应用
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
ES2831754T3 (es) 2015-11-25 2021-06-09 Cernostics Inc Métodos para predecir la progresión del esófago de Barrett
US20190064172A1 (en) * 2016-04-20 2019-02-28 Eisai Inc. Prognosis of serous ovarian cancer using biomarkers
US11136581B2 (en) * 2016-06-24 2021-10-05 University Of South Carolina Inhibin as targetable regulators of angiogenesis
TWI823836B (zh) * 2016-07-08 2023-12-01 美商建南德克公司 人類副睪蛋白４（ｈｅ４）用於評定癌症治療反應性之用途
CN109844532B (zh) * 2016-08-10 2022-06-17 米密德诊断学有限公司 分析生物数据的系统和方法
CN106520924A (zh) * 2016-10-14 2017-03-22 浙江大学 一种用于检测卵巢癌的引物组及检测方法
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
CN109480771B (zh) * 2018-10-17 2021-09-07 江西惠肽生物科技有限公司 一种卵巢肿块良恶的确定方法及确定装置
CN112946290A (zh) * 2019-12-10 2021-06-11 上海交通大学医学院附属仁济医院 细胞外基质底物反应蛋白1在制备诊断和预测卵巢癌试剂中的应用
KR102316178B1 (ko) * 2020-04-14 2021-10-22 서울대학교병원 난소암 환자의 암 재발율 또는 생존율 예측용 조성물
CN111693703B (zh) * 2020-07-17 2023-07-21 北京信诺卫康科技有限公司 Spondin 1和HE4联合用作早期卵巢癌生物标志物以及试剂盒
KR102472050B1 (ko) * 2022-03-29 2022-11-30 주식회사 아이엠비디엑스 환자 맞춤형 패널을 이용한 암의 재발을 예측하는 방법

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
US4921790A (en) * 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
JP4146512B2 (ja) 1991-03-01 2008-09-10 ダイアックス コープ． 小型タンパク質
EP0580737B1 (en) 1991-04-10 2004-06-16 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993006121A1 (en) 1991-09-18 1993-04-01 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
WO1993009668A1 (en) 1991-11-22 1993-05-27 Affymax Technology N.V. Combinatorial strategies for polymer synthesis
US5976818A (en) * 1991-12-16 1999-11-02 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies which identify the glycoprotein carrying the CA 125 epitope
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
KR20010031140A (ko) 1997-10-14 2001-04-16 루미넥스 코포레이션 정밀 형광염료 입자 및 그의 제조방법 그리고 그의 사용
WO1999023254A1 (en) 1997-10-31 1999-05-14 Affymetrix, Inc. Expression profiles in adult and fetal organs
ATE239801T1 (de) 1998-01-22 2003-05-15 Luminex Corp Mikropartikel mit multiplen fluoreszenz-signalen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US7223727B2 (en) * 1998-04-09 2007-05-29 Serono Genetics Institute S.A. GSSP4 polynucleotides and polypeptides and uses thereof
AU3897999A (en) 1998-05-14 1999-11-29 Luminex Corporation Multi-analyte diagnostic system and computer implemented process for same
AU3395900A (en) * 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US20020151681A1 (en) * 1999-03-12 2002-10-17 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US20020052308A1 (en) * 1999-03-12 2002-05-02 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030064072A9 (en) * 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030040617A9 (en) * 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20020019330A1 (en) * 1999-08-11 2002-02-14 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20030152926A1 (en) * 1999-08-11 2003-08-14 Eos Biotechnology, Inc. Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20040009494A1 (en) * 1999-08-11 2004-01-15 Richard Murray Novel methods of diagnosis of angiogenesis and other conditions, compositions, and the methods of screening for modulators
US20020015970A1 (en) * 1999-08-11 2002-02-07 Richard Murray Novel methods of diagnosis of angiogenesis, compositions, and methods of screening for angiogenesis modulators
US20020155468A1 (en) * 1999-09-23 2002-10-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
AU7832700A (en) * 1999-09-23 2001-04-24 Corixa Corporation Ovarian tumor antigen and methods of use therefor
US20020058292A1 (en) * 2000-12-08 2002-05-16 Dillon Davin C. Ovarian tumor antigen and methods of use therefor
US20020094953A1 (en) * 2000-01-31 2002-07-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030092611A9 (en) * 2000-01-31 2003-05-15 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090672A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090615A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040101927A9 (en) * 2000-01-31 2004-05-27 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020086330A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030125246A9 (en) * 2000-01-31 2003-07-03 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020061521A1 (en) * 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020086823A1 (en) * 2000-01-31 2002-07-04 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020090674A1 (en) * 2000-01-31 2002-07-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20020077270A1 (en) * 2000-01-31 2002-06-20 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030171252A9 (en) * 2000-01-31 2003-09-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20040259152A1 (en) * 2000-02-22 2004-12-23 Richard Murray Novel methods of diagnosing and screening for modulators of tissue remodeling and treating related diseases
US6773883B2 (en) * 2000-07-31 2004-08-10 The Brigham & Women's Hospital, Inc. Prognostic classification of endometrial cancer
US20020045230A1 (en) * 2000-08-14 2002-04-18 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002023201A2 (en) * 2000-09-13 2002-03-21 Zymogenetics, Inc. Use of human phermone polypeptides
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CA2443617C (en) * 2001-04-17 2013-12-10 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
US7309760B2 (en) * 2001-04-17 2007-12-18 The Board Of Trustees Of The University Of Arkansas Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
IL158397A0 (en) * 2001-04-18 2004-05-12 Genset Sa Polypeptides, their preparation and their use
US7205142B2 (en) * 2001-05-11 2007-04-17 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, CA125, and uses thereof
AU2002344326A1 (en) * 2001-05-11 2002-11-25 Sloan-Kettering Institute For Cancer Research Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
US20070015144A9 (en) * 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
AU2001286171B2 (en) * 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US7189507B2 (en) * 2001-06-18 2007-03-13 Pdl Biopharma, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7705120B2 (en) * 2001-06-21 2010-04-27 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US20040033495A1 (en) * 2001-08-03 2004-02-19 Eos Biotechnology, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US20030124579A1 (en) * 2001-09-05 2003-07-03 Eos Biotechnology, Inc. Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20070042360A1 (en) * 2001-09-17 2007-02-22 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20030232350A1 (en) * 2001-11-13 2003-12-18 Eos Biotechnology, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CN101692090B (zh) * 2002-08-06 2014-06-25 约翰霍普金斯大学 用于检测卵巢癌的生物标记的用途
AU2003288918A1 (en) * 2002-10-04 2004-05-04 Van Andel Research Institute Molecular sub-classification of kidney tumors and the discovery of new diagnostic markers
US20050181375A1 (en) * 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
WO2004075713A2 (en) * 2003-02-26 2004-09-10 Mount Sinai Hospital Multiple marker assay for detection of ovarian cancer
US20050208500A1 (en) * 2003-03-04 2005-09-22 Erlander Mark G Signatures of ER status in breast cancer
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
FR2855832B1 (fr) * 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US20070037204A1 (en) * 2003-08-08 2007-02-15 Hiroyuki ABURANTAI Gene overexpressed in cancer
AU2004264948A1 (en) 2003-08-15 2005-02-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Multifactorial assay for cancer detection
WO2005024054A1 (en) * 2003-09-05 2005-03-17 Royal Women's Hospital Diagnostic marker for ovarian cancer
CA2541804A1 (en) * 2003-10-07 2005-04-21 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
EP2026071B1 (en) * 2004-02-19 2013-07-31 Yale University Identification of cancer protein biomarkers using proteomic techniques
US20060029956A1 (en) * 2004-07-09 2006-02-09 Tripath Imaging, Inc. Methods and compositions for the detection of ovarian disease
CN106124765A (zh) * 2006-01-04 2016-11-16 富士瑞必欧美国公司 He4与其它生化标记物在卵巢癌评估中的应用

Also Published As

Publication number Publication date
BRPI0707249A2 (pt) 2011-04-26
WO2007090076A2 (en) 2007-08-09
US20070212721A1 (en) 2007-09-13
AU2007211085A1 (en) 2007-08-09
KR20080094803A (ko) 2008-10-24
EP1987360B1 (en) 2012-03-07
US20090075307A1 (en) 2009-03-19
ATE548656T1 (de) 2012-03-15
WO2007090076A3 (en) 2007-11-08
CA2637446A1 (en) 2007-08-09
JP2009524438A (ja) 2009-07-02
CN101410715A (zh) 2009-04-15
US20090068690A1 (en) 2009-03-12
WO2007090076A8 (en) 2011-03-03
EP2363711A1 (en) 2011-09-07
EP1987360A2 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
MX2008009592A (es) Metodos y composiciones para identificar pacientes con una probabilidad incrementada de tener cancer de ovario.
WO2006036788A3 (en) Methods and compositions for evaluating breast cancer prognosis
EP2293069A3 (en) Methods and compositions for the detection of cervical disease
ATE419534T1 (de) Verwendung von c3a und derivaten als biomarker für kolorektaladenom und/oder -karzinom ; nachweisverfahren und testsystem damit
JP2011506941A5 (es)
MX344053B (es) Metodos para determinar isotipos de anticuerpos anti-farmacos.
WO2008151110A3 (en) Molecular diagnosis and typing of lung cancer variants
WO2010096154A3 (en) Compositions and methods for diagnosis and prognosis of colorectal cancer
EP1930445A4 (en) KIT AND METHOD FOR DETECTING UROTHELIAL CANCER
DK2038430T3 (da) Toll-Like-Receptor-4-dysfunktion og de biologiske anvendelser deraf
DE60315715D1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ES2792680T3 (es) Método para identificar un biomarcador indicativo de una respuesta reducida a fármacos utilizando un ensayo de desplazamiento térmico
ATE538217T1 (de) Erkennung von ektopischen schwangerschaften
WO2019089858A3 (en) Methods of assessing or monitoring a response to a cell therapy
ES2863274T3 (es) Biomarcador de muerte celular
WO2013003216A4 (en) Methods for determining response to neoadjuvant therapy and survival using microrna-10b
DE602005026587D1 (de) Verwendung eines endoplasmin-fragments und von derivaten davon als biomarker für kolorektaladenom und/oder -karzinom; nachweisverfahren und testsystem
ITPD20110201A1 (it) Metodo per la prognosi di tumori al seno basata sull'espressione dell'enzima prolil isomerarasi pin1 in combinazione con mutazioni del gene tp53
WO2010142651A3 (en) Method for determining the risk of developing brain metastasis, and a kit to carry out said method
DK1416278T3 (da) Fremgangsmåder til forbedret diagnosticering af dysplasier
KR102657188B1 (ko) 분리된 세포로부터 프라이머를 이용하여 세포노화 바이오 마커를 검출하는 방법
KR102657190B1 (ko) 분리된 세포로부터 프라이머를 이용하여 세포노화 바이오 마커 gas2l3 및 amot를 검출하는 방법
KR102639826B1 (ko) 세포노화 바이오 마커 gas2l3 및 amot의 rt-pcr 검출을 이용한 세포 노화를 검출하는 방법
KR102657189B1 (ko) 분리된 세포로부터 프라이머를 이용하여 세포노화 바이오 마커 gas2l3 및 wdr76를 검출하는 방법
Cisarovsky et al. Biomarker Development in Targeting Cancer Epigenetic

Legal Events

Date Code Title Description
FA Abandonment or withdrawal